A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium

Clinical Therapeutics

Volumn 27, Issue 1, 2005, Pages 111-124

  Demyttenaere, Koen ^a   Hemels, Michiel E H ^b   Hudry, Joumana ^b   Annemans, Lieven ^c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Lundbeck   (France)

^c GHENT UNIVERSITY   (Belgium)

^d Health Economics and Disease Management   (Belgium)

Author keywords

Belgium; Cost effectiveness; Depression; Escitalopram; Severe

Indexed keywords

CITALOPRAM; ESCITALOPRAM; VENLAFAXINE;

ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG SAFETY; DRUG SCREENING; FRICTION; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; LITERATURE; MAJOR DEPRESSION; MEDICAL CARE; MEDICAL SOCIETY; MEDICAL SPECIALIST; MONEY; OBSERVATION; OUTCOMES RESEARCH; PATIENT REFERRAL; PROBABILITY; RATING SCALE; REMISSION; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIDE EFFECT;

EID: 14844337907     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.01.001     Document Type: Article

References (32)

1. Greenberg P.E., Stiglin L.E., Finkelstein S.N., and Berndt E.R. The economic burden of depression in 1990 J Clin Psychiatry 54 1993 405 418
2. Simon G.E., Revicki D., and Heiligenstein J. Recovery from depression, work productivity, and health care costs among primary care patients Gen Hosp Psychiatry 22 2000 153 162
3. Thompson D., and Richardson E. Current issues in the economics of depression management Curr Psychiatry Rep 1 1999 125 134
4. Lepine J.P., Gastpar M., Mendlewicz J., and Tylee A. Depression in the community: The first pan-European study DEPRES (Depression Research in European Society) Int Clin Psychopharmacol 12 1997 19 29
5. [in French] Bruffaerts R., Bonnewyn A., and Van Oyen H. Patterns of service use for mental health disorders in Belgium. Results of the European Study on Epidemiology of Mental Disorders (ESEMeD) Rev Med Liege 59 2004 136 144
6. [in French] Ansseau M. Thesocio-economics of depression Rev Med Liege 53 1998 308 310
7. Annemans L., Crott R., and Degraeve D. Pharmaco-Economic Committee PEC of the Belgian Society for Pharmacoepidemiology Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium Pharm World Sci 24 2002 5 7
8. Einarson T.R. Evidence based review of escitalopram in treating major depressive disorder in primary care Int Clin Psychopharmacol 19 2004 305 310
9. Gorman J.M., Korotzer A., and Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials CNS Spectr 7 Suppl 4 2002 40 44
10. François C., Sintonen H., and Toumi M. Introduction of escitalopram, a new SSRI in Finland: Comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment ofdepression and estimation of the budgetary impact J Med Econ 5 2002 91 107
11. François C., Toumi M., and Aakhus A.M. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor: Comparison of cost-effectiveness between escitalopram,citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway Eur J Health Econ 4 2003 12 19
12. Hemels M.E., Kasper S., Walter E., and Einarson T.R. Cost-effectiveness analysis of escitalopram: A new SSRI in the first-line treatment of major depressive disorder in Austria Curr Med Res Opin 20 2004 869 878
13. Montgomery S.A., and Åsberg M. A new depression scale designed to be sensitive to change Br J Psychiatry 134 1979 382 389
14. Muller M.J., Himmerich H., Kienzle B., and Szegedi A. Differentiating moderate and severe depression using the Montgomery-Åsberg depression rating scale (MADRS) J Affect Disord 77 2003 255 260
15. Niklson I.A., and Reimitz P.E. Baseline characteristics of major depressive disorder patients in clinical trials in Europe and United States: Is there a transatlantic difference? J Psychiatr Res 35 2001 71 81
16. Buxton M.J., Drummond M.F., and Van Hout B.A. Modelling in economic evaluation: An unavoidable fact of life Health Econ 6 1997 217 227
17. Lepola U.M., Loft H., and Reines E.H. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care Int Clin Psychopharmacol 18 2003 211 217
18. Montgomery S.A., Huusom A.K., and Bothmer J. A randomised study comparing escitalopram with ven lafaxine XR in primary care patients with major depressive disorder Neuropsychobiology 50 2004 57 64
19. Montgomery S.A., Rasmussen J.G., and Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression Int Clin Psychopharmacol 8 1993 181 188
20. Robert P., and Montgomery S.A. Citalopram in doses of 20-60 mg is effective in depression relapse preven tion: A placebo-controlled 6 month study Int Clin Psychopharmacol 10 Suppl 1 1995 29 35
21. Demyttenaere K., Enzlin P., and Dewe W. Compliance with antidepressants in a primary care setting: Be yond lack of efficacy and adverse events J Clin Psychiatry 62 Suppl 22 2001 30 33
22. Patris M., Bouchard J.M., and Bougerol T. Citalopram versus fluoxetine: A double-blind, controlled, multi centre, phase III trial in patients with unipolar major depression treated ingeneral practice Int Clin Psychopharmacol 11 1996 129 136
23. Bougerol T., Scotto J.-C., and Patris M. Citalopram and fluoxetine in major depression. Comparison of two clinical trials in a psychiatrist setting and in general practice Clin Drug Invest 14 1997 77 89
24. Khan A., Khan S.R., Leventhal R.M., and Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration Database Int J Neuropsychopharmacol 4 2001 113 118
25. Fava M. Management of nonresponse and intolerance: Switching strategies J Clin Psychiatry 61 Suppl 2 2000 10 12
26. Joffe R.T., Levitt A.J., Sokolov S.T., and Young L.T. Response to an open trial of a second SSRI in major depression J Clin Psychiatry 57 1996 114 115
27. Hutubessy R.C., van Tulder M.W., Vondeling H., and Bouter L.M. Indirect costs of back pain in the Nether lands: A comparison of the human capital method with the friction cost method Pain 80 1999 201 207
28. Central Bureau of Statistics Web site. Consumer price index [in Dutch].
29. Kroenke K., West S.L., and Swindle R. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial JAMA 286 2001 2947 2955
30. Straton J.B., and Cronholm P. Are paroxetine, fluoxetine, and sertraline equally effective for depression? J Fam Pract 51 2002 285
31. Sanchez C., Bergqvist P.B., and Brennum L.T. Escitalopram, the S-(+)enantiomer of citalopram, is a selec tive serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities Psychopharmacology (Berl) 167 2003 353 362
32. Kind P., and Sorensen J. The costs of depression Int Clin Psychopharmacol 7 1993 191 195